{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T17:55:50Z","timestamp":1778349350992,"version":"3.51.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2000,3,1]],"date-time":"2000-03-01T00:00:00Z","timestamp":951868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2000,3,1]],"date-time":"2000-03-01T00:00:00Z","timestamp":951868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2000,3,1]]},"DOI":"10.1038\/sj.bmt.1702178","type":"journal-article","created":{"date-parts":[[2002,9,4]],"date-time":"2002-09-04T15:44:36Z","timestamp":1031154276000},"page":"465-470","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["Myeloablative chemotherapy with stem cell rescue for the treatment of primary systemic amyloidosis: a status report"],"prefix":"10.1038","volume":"25","author":[{"given":"MA","family":"Gertz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MQ","family":"Lacy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Dispenzieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2000,3,9]]},"reference":[{"key":"BF1702178_CR1","first-page":"45","volume":"32","author":"RA Kyle","year":"1995","unstructured":"Kyle RA, Gertz MA . Primary systemic amyloidosis: clinical and laboratory features in 474 cases Semin Hematol 1995 32: 45\u201359","journal-title":"Semin Hematol"},{"key":"BF1702178_CR2","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood.V93.3.1062","volume":"93","author":"RA Kyle","year":"1999","unstructured":"Kyle RA, Gertz MA, Greipp PR et al. Long-term survival (10 years or more) in 30 patients with primary amyloidosis Blood 1999 93: 1062\u20131066","journal-title":"Blood"},{"key":"BF1702178_CR3","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1001\/jama.1969.03160090040009","volume":"208","author":"R Alexanian","year":"1969","unstructured":"Alexanian R, Haut A, Khan AU et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens JAMA 1969 208: 1680\u20131685","journal-title":"JAMA"},{"key":"BF1702178_CR4","doi-asserted-by":"publisher","first-page":"466","DOI":"10.7326\/0003-4819-82-4-466","volume":"82","author":"HJ Cohen","year":"1975","unstructured":"Cohen HJ, Lessin LS, Halal J, Burkholder P . Resolution of primary amyloidosis during chemotherapy. Studies in a patient with nephrotic syndrome Ann Intern Med 1975 82: 466\u2013473","journal-title":"Ann Intern Med"},{"key":"BF1702178_CR5","doi-asserted-by":"publisher","first-page":"281","DOI":"10.7326\/0003-4819-83-2-281","volume":"83","author":"III Horne MK","year":"1975","unstructured":"Horne MK III . Improvement in amyloidosis (letter) Ann Intern Med 1975 83: 281\u2013282","journal-title":"Ann Intern Med"},{"key":"BF1702178_CR6","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/S0002-9343(97)89487-9","volume":"100","author":"M Skinner","year":"1996","unstructured":"Skinner M, Anderson J, Simms R et al. Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only Am J Med 1996 100: 290\u2013298","journal-title":"Am J Med"},{"key":"BF1702178_CR7","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1056\/NEJM199704243361702","volume":"336","author":"RA Kyle","year":"1997","unstructured":"Kyle RA, Gertz MA, Greipp PR et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine New Engl J Med 1997 336: 1202\u20131207","journal-title":"New Engl J Med"},{"key":"BF1702178_CR8","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/S0049-0172(05)80006-X","volume":"24","author":"MA Gertz","year":"1994","unstructured":"Gertz MA, Kyle RA . Amyloidosis: prognosis and treatment Semin Arthritis Rheum 1994 24: 124\u2013138","journal-title":"Semin Arthritis Rheum"},{"key":"BF1702178_CR9","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/blood.V77.2.257.257","volume":"77","author":"MA Gertz","year":"1991","unstructured":"Gertz MA, Kyle RA, Greipp PR . Response rates and survival in primary systemic amyloidosis Blood 1991 77: 257\u2013262","journal-title":"Blood"},{"key":"BF1702178_CR10","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1056\/NEJM198405243102104","volume":"310","author":"B Barlogie","year":"1984","unstructured":"Barlogie B, Smith L, Alexanian R . Effective treatment of advanced multiple myeloma refractory to alkylating agents New Engl J Med 1984 310: 1353\u20131356","journal-title":"New Engl J Med"},{"key":"BF1702178_CR11","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1038\/bjc.1998.577","volume":"78","author":"AM Wardley","year":"1998","unstructured":"Wardley AM, Jayson GC, Goldsmith DJ et al. The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone Br J Cancer 1998 78: 774\u2013776","journal-title":"Br J Cancer"},{"key":"BF1702178_CR12","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/0002-9343(77)90543-5","volume":"63","author":"Jr Case DC","year":"1977","unstructured":"Case DC Jr, Lee DJ III, Clarkson BD . Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol Am J Med 1977 63: 897\u2013903","journal-title":"Am J Med"},{"key":"BF1702178_CR13","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1002\/(SICI)1097-0142(19970415)79:8<1561::AID-CNCR18>3.0.CO;2-W","volume":"79","author":"MM Oken","year":"1997","unstructured":"Oken MM, Harrington DP, Abramson N et al. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479 Cancer 1997 79: 1561\u20131567","journal-title":"Cancer"},{"key":"BF1702178_CR14","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1200\/JCO.1999.17.1.262","volume":"17","author":"MA Gertz","year":"1999","unstructured":"Gertz MA, Lacy MQ, Lust JA et al. Prospective randomized trial of melphalan and prednisone versus vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of primary systemic amyloidosis J Clin Oncol 1999 17: 262\u2013267","journal-title":"J Clin Oncol"},{"key":"BF1702178_CR15","doi-asserted-by":"publisher","first-page":"508","DOI":"10.7326\/0003-4819-122-7-199504010-00005","volume":"122","author":"M van Buren","year":"1995","unstructured":"van Buren M, Hene RJ, Verdonck LF et al. Clinical remission after syngeneic bone marrow transplantation in a patient with AL amyloidosis Ann Intern Med 1995 122: 508\u2013510","journal-title":"Ann Intern Med"},{"key":"BF1702178_CR16","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s002590050272","volume":"25","author":"PN Hawkins","year":"1998","unstructured":"Hawkins PN, Aprile C, Capri G et al. Scintigraphic imaging and turnover studies with iodine-131 labelled serum amyloid P component in systemic amyloidosis Eur J Nucl Med 1998 25: 701\u2013708","journal-title":"Eur J Nucl Med"},{"key":"BF1702178_CR17","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1046\/j.1365-2141.1998.00527.x","volume":"100","author":"JD Gillmore","year":"1998","unstructured":"Gillmore JD, Davies J, Iqbal A et al. Allogeneic bone marrow transplantation for systemic AL amyloidosis Br J Haematol 1998 100: 226\u2013228","journal-title":"Br J Haematol"},{"key":"BF1702178_CR18","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/sj.bmt.1700983","volume":"20","author":"B Guillaume","year":"1997","unstructured":"Guillaume B, Straetmans N, Jadoul M et al. Allogeneic bone marrow transplantation for AL amyloidosis Bone Marrow Transplant 1997 20: 907\u2013908","journal-title":"Bone Marrow Transplant"},{"key":"BF1702178_CR19","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1182\/blood.V87.7.3063.bloodjournal8773063","volume":"87","author":"P Moreau","year":"1996","unstructured":"Moreau P, Milpied N, de Faucal P et al. High-dose melphalan and autologous bone marrow transplantation for systemic AL amyloidosis with cardiac involvement (letter) Blood 1996 87: 3063\u20133064","journal-title":"Blood"},{"key":"BF1702178_CR20","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1046\/j.1537-2995.1998.38198141500.x","volume":"38","author":"RL Comenzo","year":"1998","unstructured":"Comenzo RL, Michelle D, LeBlanc M et al. Mobilized CD34+ cells selected as autografts in patients with primary light-chain amyloidosis: rationale and application Transfusion 1998 38: 60\u201369","journal-title":"Transfusion"},{"key":"BF1702178_CR21","doi-asserted-by":"publisher","first-page":"553","DOI":"10.7326\/0003-4819-123-7-199510010-00018","volume":"123","author":"HM Lokhorst","year":"1995","unstructured":"Lokhorst HM, Verdonck LF . Intensive therapy in AL amyloidosis and light-chain deposition disease (reply to letter) Ann Intern Med 1995 123: 553","journal-title":"Ann Intern Med"},{"key":"BF1702178_CR22","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1182\/blood.V88.7.2801.bloodjournal8872801","volume":"88","author":"RL Comenzo","year":"1996","unstructured":"Comenzo RL, Vosburgh E, Simms RW et al. Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients Blood 1996 88: 2801\u20132806","journal-title":"Blood"},{"key":"BF1702178_CR23","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1182\/blood.V91.10.3662","volume":"91","author":"RL Comenzo","year":"1998","unstructured":"Comenzo RL, Vosburgh E, Falk RH et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients Blood 1998 91: 3662\u20133670","journal-title":"Blood"},{"key":"BF1702178_CR24","first-page":"324A","volume":"92","author":"RL Comenzo","year":"1998","unstructured":"Comenzo RL, Falk RH, Sanchorawala V et al. Treating AL amyloidosis (AL) with dose-intensive melphalan: outcomes in 102 patients (abstract) Blood 1998 92: 324A","journal-title":"Blood"},{"key":"BF1702178_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/sj.bmt.1701089","volume":"21","author":"JM Goldman","year":"1998","unstructured":"Goldman JM, Schmitz N, Niethammer D, Gratwohl A . Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe in 1998. Accreditation Sub-Committee of the European Group for Blood and Marrow Transplantation Bone Marrow Transplant 1998 21: 1\u20137","journal-title":"Bone Marrow Transplant"},{"key":"BF1702178_CR26","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1046\/j.1365-2141.1998.00772.x","volume":"101","author":"P Moreau","year":"1998","unstructured":"Moreau P, Leblond V, Bourquelot P et al. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients Br J Haematol 1998 101: 766\u2013769","journal-title":"Br J Haematol"},{"key":"BF1702178_CR27","first-page":"pp 102","volume-title":"Amyloid and Amyloidosis 1998","author":"JD Gillmore","year":"1999","unstructured":"Gillmore JD, Apperley JF, Craddock C et al. High-dose melphalan and stem cell rescue for AL amyloidosis. In: Kyle RA, Gertz MA (eds) Amyloid and Amyloidosis 1998 Parthenon Publishing: Pearl River, New York 1999 pp 102\u2013104"},{"key":"BF1702178_CR28","first-page":"S234","volume":"41","author":"Z Amoura","year":"1998","unstructured":"Amoura Z, Leblond V, Azar N et al. High-dose therapy and autologous stem cell transplantation (ASCT) for systemic amyloidosis (AL): report of 9 cases (abstract) Arthritis Rheum 1998 41: S234","journal-title":"Arthritis Rheum"},{"key":"BF1702178_CR29","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3109\/10428199709059685","volume":"27","author":"KR Desikan","year":"1997","unstructured":"Desikan KR, Dhodapkar MV, Hough A et al. Incidence and impact of light chain associated (AL) amyloidosis on the prognosis of patients with multiple myeloma treated with autologous transplantation Leuk Lymphoma 1997 27: 315\u2013319","journal-title":"Leuk Lymphoma"},{"key":"BF1702178_CR30","first-page":"633","volume":"16","author":"S Ager","year":"1995","unstructured":"Ager S, Mahendra P, Jestice HK et al. The use of non-cryopreserved peripheral blood progenitor cells in autologous transplantation (letter) Bone Marrow Transplant 1995 16: 633\u2013634","journal-title":"Bone Marrow Transplant"},{"key":"BF1702178_CR31","first-page":"1087","volume":"326","author":"J Mehta","year":"1992","unstructured":"Mehta J, Nagler A, Slavin S . Marrow transplantation in multiple myeloma (letter) New Engl J Med 1992 326: 1087","journal-title":"New Engl J Med"},{"key":"BF1702178_CR32","first-page":"85","volume":"11","author":"I Majolino","year":"1993","unstructured":"Majolino I, Marceno R, Pecoraro G et al. Autologous stem cell transplantation in amyloidosis AL (letter) Bone Marrow Transplant 1993 11: 85","journal-title":"Bone Marrow Transplant"},{"key":"BF1702178_CR33","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1046\/j.1365-2141.1997.303194.x","volume":"99","author":"JD Gillmore","year":"1997","unstructured":"Gillmore JD, Hawkins PN, Pepys MB . Amyloidosis: a review of recent diagnostic and therapeutic developments Br J Haematol 1997 99: 245\u2013256","journal-title":"Br J Haematol"},{"key":"BF1702178_CR34","first-page":"360B (Abstr.)","volume":"92","author":"G Akpek","year":"1998","unstructured":"Akpek G, Colarusso T, Lerner A et al. Immune reconstitution after autologous blood stem cell transplantation (ABSCT) in patients with AL amyloidosis (AL) Blood 1998 92: 360B (Abstr.)","journal-title":"Blood"},{"key":"BF1702178_CR35","first-page":"pp 169","volume-title":"Amyloid and Amyloidosis 1998","author":"MA Kazmi","year":"1999","unstructured":"Kazmi MA, Schey SA . Morbidity associated with high dose therapy in primary amyloidosis. In: Kyle RA, Gertz MA (eds) Amyloid and Amyloidosis 1998 Parthenon Publishing: Pearl River, New York 1999 pp 169\u2013171"},{"key":"BF1702178_CR36","unstructured":"Gertz M, Lacy M, Gastineau D et al. Blood stem cell transplantation as initial therapy for primary systemic amyloidosis (AL) Bone Marrow Transplant (in press)"},{"key":"BF1702178_CR37","first-page":"20a (Abstr.)","volume":"18","author":"A Dispenzieri","year":"1999","unstructured":"Dispenzieri A, Lacy MQ, Kyle RA et al. AL amyloidosis is a favorable independent prognostic factor for survival of 234 patients with primary systemic amyloidosis (AL) functionally eligible for peripheral blood stem cell transplantation Proc ASCO 1999 18: 20a (Abstr.)","journal-title":"Proc ASCO"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/1702178","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1702178.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1702178.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T21:50:51Z","timestamp":1648072251000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/1702178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,3,1]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2000,3,1]]}},"alternative-id":["BF1702178"],"URL":"https:\/\/doi.org\/10.1038\/sj.bmt.1702178","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,3,1]]},"assertion":[{"value":"3 June 1999","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 1999","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2000","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}